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Summary 6-Mercaptopurine (MP)-sensitive and -resistant cell culture lines were used to further characterize
the apparent ability of MP nucleotide derivatives to overcome resistance to the parent drug. 6-Mercapto-
purine-9-f,-D-ribofuranoside 5'-monophosphate [MPRP], bis(6-mercaptopurine-9-fl-D-ribofuranoside)-5',
5"'-monophosphate [bis(MPR)P], bis(02',03'-dibutyryl-6-mercaptopurine-9-fl-D-ribofuranoside)-5', 5"'-mono-
phosphate [bis(dibut.MPR)P], and 02',03'-dibutyryl-6-mercaptopurine-9-fl-D-ribofuranoside 5'-monophosphate
[dibut.MPRP] were tested for cytotoxic and/or growth inhibitory effects against MP-resistant sublines of
V79 Chinese hamster lung fibroblasts (CH/TG) and L1210 mouse leukaemia cells (L1210/MPR) in which
deficiencies of hypoxanthine-guanine phosphoribosyltransferase, and hence drug nucleotide forming capacity
were the basis of resistance. L1210/MPR cells were totally resistant to 1 mM 6-mercaptopurine-9-f-D-
ribofuranoside [MPR] and 2mM MPRP, but were inhibited by high concentrations (>0.25mM) of
bis(MPR)P. These results suggested that bis(MPR)P was taken up by celis as the intact molecule since MPR
and MPRP were its extracellular breakdown products. L1210/MPR cells were much more sensitive to the
lipophilic bis(dibut.MPR)P derivative which had a predominantly cytotoxic action as judged by trypan blue
staining and the ability of treated cells to produce macroscopic colonies in soft agar medium. However,
cells killed by bis(dibut.MPR)P did not disintegrate appreciably over periods of up to 10 days. The effects of
bis(dibut.MPR)P were probably the result of cellular uptake of the intact molecule. Dibut.MPRP showed
minimal ability to inhibit L1210/MPR cells although this compound was a possible breakdown product of
bis(dibut.MPR)P and a source of the same extracellular degradation products. The median cell size decreased
in L1210/MPR cultures during exposure to both bis(MPR)P and bis(dibut.MPR)P. This effect was elicited more
rapidly and at lower concentration by bis(dibut.MPR)P than by bis(MPR)P. In contrast, sodium butyrate,
a breakdown product of bis(dibut.MPR)P induced increases in cell size at high concentration. Bis
(dibut.MPR)P was also cytotoxic to MP-resistant CH/TG cells and was approximately 300 times more effec-
tive than bis(MRP)P and MPR which exhibited similar activity against this cell line. Bis(dibut.MPR)P
and dibut.MPRP were equivalent and less active than MPR in their effect- on MP-sensitive L1210/0 cells
where their predominant mechanism of action was via degradation to release MPR. Cytotoxic concentrations
of bis(MPR)P and bis(dibut.MPR)P did not affect the endogenous pools of purine and pyrimidine ribo-
nucleoside triphosphates of L1210/MPR cells, nor were the derivatives incorporated into nucleic acids of
the HGPRT-deficient cells as 6-thioguanine nucleotides. However, both compounds inhibited the incorporation
of radiolabelled uridine, thymidine and leucine into macromolecules in a similar fashion, except that these
effects were elicited much more rapidly and at lower concentration by bis(dibut.MPR)P. It was concluded that
intracellular bis(MPR)P derived from extracellular bis(MPR)P or bis(dibut.MPR)P was acting as such on
L12I0/MPR cells and not as a "prodrug" of MPRP.
The work described in this paper forms part of a analogues which would not normally be
project concerned with the development of effective phosphorylated by cellular enzymes. In order to
"prodrugs" for nucleotides of purine and investigate the factors involved in attempts to
pyrimidine antimetabolites. These are intended on achieve this aim we are presently studying 6-
the one hand to circumvent mechanisms of cellular mercaptopurine (MP) derivatives, both* for their
resistance to the parent drugs involving reduced own sake and as a model system for other
efficiency of intracellular drug nucleotide antimetabolities. The choice of MP is based upon
formation, and on the other hand as a means of two considerations; firstly, much is known about
introducing into cells, nucleotide derivatives of the metabolism, metabolic effects and mechanism
of action of this thiopurine (Tidd & Paterson,
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system facilitates analysis of MP derivatives,
metabolites and breakdown products in chemically
complex cell cultures.
In drug-sensitive cells, MP is converted to 6-
mercaptopurine-9-f,-D-ribofuranoside 5'-monophos-
phate (MPRP) by hypoxanthine-guanine phosphori-
bosyltransferase (HGPRT) as the first obligatory
step in its mechanism of action. MPRP inhibits
purine nucleotide biosynthesis de novo and purine
nucleotide interconversions; however, it is the
further metabolism of the drug nucleotide to 6-
thioguanine nucleotides and subsequent incor-
poration of 6-thioguanine deoxyribonucleotide into
DNA that is primarily responsible for the anti-
leukaemic activity of MP (Tidd & Paterson, 1974a,
b; Nelson et al., 1975).
6-Mercaptopurine-9-f3-D-ribofuranoside (MPR) is
essentially equivalent to MP in its action. The
nucleoside is metabolized for the most part through
cleavage by purine nucleoside phosphorylase with
release of MP which is then converted to MPRP
by HGPRT. However, slightly greater growth in-
hibitory effects are sometimes observed with MPR
than with MP against cell lines that are relatively
resistant to the thiopurines (Tidd, 1984). Con-
sequently, we have used MPR and not MP as a
control for investigations with MPR nucleotide
derivatives (Tidd et al., 1982a, b). Cellular resis-
tance to MP is generally associated with reduced
nett intracellular accumulation of MPRP. This is
achieved by a number of mechanisms including
suppression or loss of HGPRT activity (Tidd, 1984).
Exogenous MPRP is unable to circumvent resistance
to MP because cell membranes are relatively
impermeable to the highly charged nucleoside 5'-
monophosphate and phosphohydrolases bound to
external cell surfaces readily dephosphorylate MPRP
(Tidd et al., 1982a). However, Montgomery et al.
(1963) reported that bis(6-mercaptopurine-9-f3-D-
ribofuranoside)-5',5"'-phosphate [trivial name, bis
(thioinosine)-5',5"'-phosphate; abbreviation bis
(MPR)P] inhibited growth of an HGPRT-deficient,
MP-resistant human epidermoid cell subline,
HEp No. 2/MP in culture, whilst MP, MPR and
MPRP were without significant effect. This com-
pound may be looked upon as an MPR-5'-ester
of MPRP in which the charge on the phosphate
of MPRP is reduced by esterification with the
second MPR group. The derivative is also immune
to dephosphorylation by phosphohydrolases,
although phosphodiesterases cleave the molecule
to yield MPR and MPRP. Montgomery et al. (1963)
suggested that bis(MPR)P may have been taken up
as the intact molecule by HEp No. 2/MP cells and
that subsequent intracellular hydrolysis catalysed
by phosphodiesterases generated cytotoxic concen-
trations of MPRP in the HGPRT-deficient cells,
thereby circumventing the mechanism of MP-
resistance.
We have previously reported that bis(MPR)P
exhibited much poorer growth inhibitory activity
against our HGPRT-deficient mouse leukaemia
L1210/MPR subline in culture than that reported by
Montgomery et al. (1963) with HEp No.2/MP cells.
However, the compound did suppress culture growth
in concentrations at which MPR was without effect
(Tidd et al., 1982b). In contrast, bis(MPR)P was no
different from MPR in terms of growth inhibition
induced in HGPRT-deficient Chinese hamster,
CH/TG cell cultures. These differences from
Montgomery's results were related at least in part
to the observed degradation of bis(MPR)P by
phosphodiesterases present in the sera components
ofthe tissue culture media and to possible variations
with cell type in the efficiency of uptake of the
negatively charged, hydrophilic bis(MPR)P molecules
(Tidd et al., 1982b). Esterification of the sugar
2' and 3' hydroxyl groups ofbis(MPR)P with butyric
acid gave rise to a new derivative, bis(02,03-
dibutyryl -6-mercaptopurine - 9-, -D-ribofurano -
side)-5',5"'-monophosphate [abbreviation bis
(dibut.MPR)P] which was shown to be consider-
ably more resistant to degradation by serum
enzymes than was bis(MPR)P (Tidd et al., 1982b).
Preliminary growth inhibition experiments demon-
strated that the lipophilic butyryl compound was
also much more effective than bis(MPR)P against
L1210/MPR cells, although it appeared initially
to be cytostatic rather than cytotoxic in its action
at low concentrations. The greater activity of bis
(dibut.MPR)P relative to bis(MPR)P was assumed
to result both from the increased stability of the
former compound in tissue culture media and
possibly from enhanced uptake of the lipophilic
molecules by cells.
In the present paper we report the results of a
detailed investigation of the effects of bis(MPR)P
and bis(dibut.MPR)P on L1210/0 and L1210/MPR
cell growth and survival. We also demonstrate that
in contrast to the situation with bis(MPR)P, CH/TG
cells were far more sensitive to bis(dibut.MPR)P
than they were to MPR. The effects of bis
(dibut.MPR)P on L1210/MPR culture growth are
also compared with those of 02',03'-dibutyryl-6-
mercaptopurine-9-fJ-D-ribofuranoside 5'-mono-
phosphate (dibut.MPRP), where the latter com-
pound may be looked upon as a butyryl nucleo-
tide control for the former derivative. Bis(MPR)P
and bis(dibut.MPR)P apparently acted by the same
biochemical mechanism on thiopurine-resistant cells,
producing drastic inhibitions of the utilization of
exogenous radiolabelled precursors as measured by
their incorporation into RNA, DNA and protein.
These effects were elicited much more rapidly by
bis(dibut.MPR)P than by bis(MPR)P, suggesting
that the butyryl groups did indeed facilitate
cellular uptake of the intact negatively charged
bis(MPR)P molecules.6-MERCAPTOPURINE NUCLEOTIDE DERIVATIVES 507
Materials and methods
Cell cultures
The origins and methods of culture of the parent
thiopurine-sensitive mouse leukaemia L1210/0 and
Chinese hamster CH/0 cell lines, and their
thiopurine-resistant sublines, L1210/MPR and
CH/TG have been reported previously (Tidd et al.,
1982a, b). L1210/MPR cells were also adapted to
growth in Fischer's medium containing 2%
Ultroser G serum substitute (LKB Instruments
Limited, Croydon, Surrey) as a replacement for
horse serum. The serum substitute contained no
phosphodiesterase I activity and therefore these
cultures were used to determine the extent to which
serum phosphodiesterases limited the efficacy of
bis(MPR)P. Drugs. were added as filter-sterilized
solutions in 0.9% NaCl or as the requisite volume
of a solution in tissue culture medium in the case of
bis(dibut.MPR)P. Cells were enumerated with a
Model ZB Coulter Counter (Coulter Electronics
Limited, Luton, Bedfordshire). The same instru-
ment which incorporates a pulse height analyzer
was used to monitor cell volume distributions. The
median cell volume was determined as the lower
pulse height threshold setting which reduced the cell
counts recorded to one half of the total.
Cell viability assays
Intact L1210 cells were recognized by their ability
to exclude trypan blue stain (0.4% in Hanks'
balanced salt solution; Gibco Europe Ltd). One
part of stain solution was added to two parts of
culture suspension and staining and non-staining
cells were counted in a haemocytometer.
The proliferative capacity of drug-treated L1210
cultures was determined by the ability of viable
stem cells to form macroscopic colonies in soft agar
medium (Chu & Fischer, 1968). Plating efficiencies
for untreated control cells were 50 to 60%.
The fractions of Chinese hamster cells surviving
drug treatments were also determined by a cloning
assay in which small known numbers of cells (100-
10,000) were cultured under standard conditions.
Cell colonies were stained with 0.38% alkaline
methylene blue, washed with water and counted.
Plating efficiencies for untreated control cells were
between 65 to 75%.
Chemical syntheses
MPRP, bis(MPR)P and bis(dibut.MPR)P were
prepared from MPR (Sigma Chemical Company
Limited, Poole, Dorset) as previously described
(Tidd et al., 1982a, b).
Dibut.MPRP, a new derivative, was prepared
from anhydrous MPRP pyridinium salt by reaction
at room temperature with butyric anhydride (20
equivalents) in anhydrous dimethylformamide/
pyridine (8: 1) solution containing 4-dimethylamino-
pyridine catalyst (0.4 equivalents). The reaction
and subsequent purification were monitored by
thin layer chromatography on Merck 5 x 10cm
silica gel 60F254 pre-coated plates (BDH Chemicals
Limited, Enfield, Middlesex) developed with
chloroform/methanol/water, 65:24:4 by volume,
and by high performance liquid chromatography on
a Whatman Partisil-10 ODS-3 reverse phase
analytical column (Chromatography Services
Limited, Wirral, Merseyside) eluted with 40%
methanol/water at 2mlmin-1. The reaction was
complete by 24h at which time an excess of water
and 2-mercaptoethanol were added with ice cooling.
The solvent was removed in vacuo, and the residue
dissolved in dichloromethane and washed
successively with 0.5 N hydrochloric acid and water.
Dichloromethane was removed under reduced
pressure, the residue dissolved in 50%
methanol/water and pure dibut.MPRP isolated by
high performance preparative liquid chromato-
graphy on a 25cmx2.2cm ID column (Anachem
Ltd., Luton, Bedfordshire) packed with Whatman
LRP-2 reverse phase support (Chromatography
Services Ltd.) The product was eluted with a
gradient of 0 to 40% methanol/water. The bulk of
the solvent was removed from the pure
dibut.MPRP fraction under reduced pressure and
residual water was elimated by lyophilization.
Analysis of dibut.MPRP, free acid, monohydrate
C18H25N409PS.H20
Calculated: C 41.38 H 5.21 N 10.72 S 6.14
Found: C41.79 H 4.85 N 10.58 S 6.42
The compound was converted to the sodium salt
in preparing aqueous solutions for use in the
experiments described below.
Radiolabelledprecursor incorporation measurements
[6-3H]Thymidine (27Cimmol -1, 1.0mCiml-1),
[5-3H] uridine (28Cimmol-1, 1.0mCiml-1) and L-
[4,5-3H] leucine (130Cimmol -1, 1.0mCiml-1) were
purchased from Amersham International plc,
Amersham, Bucks. For determination of incor-
poration of [3H]-thymidine into acid-soluble
nucleotide pools and DNA of CH/TG cells, 2.5,uCi
of isotope was added to replicate 5 ml cultures in
50ml disposable culture flasks at 37° and at
predetermined intervals thereafter the culture fluids
were rapidly aspirated and the cell sheets washed
with 0.9% NaCl solution at 00. The cells were then
extracted with 1 ml 4% perchloric acid at 0°, the
acid extracts neutralized with 6N potassium
hydroxide at 0°, and insoluble potassium508 H.P. JOHNSTON et al.
perchlorate removed by centrifugation. Acid
insoluble cellular material was dissolved in 1 ml 1 N
sodium hydroxide and incubated at 370 for 5h to
hydrolyze RNA. Protein and DNA were
reprecipitated by addition of 0.3ml 42% perchloric
acid at 0°. Radioactivity in the acid soluble and
DNA fractions was determined by liquid
scintillation counting.
For measurement of the progressive effects of
continuous exposure to the drugs on the ability of
L1210/MPR cells to incorporate precursors into
macromolecules, multiple 1 ml samples of the
cultures were removed at various times and
incubated at 37° with 2.5MCi of each isotope
separately for 10min ([3H]-thymidine, [3H]-uridine)
and 30min ([3H]-leucine). Cells were collected by
centrifugation and processed as for CH/TG cells
thereafter. Isotope incorporations were linear over
the course of 1 h under these assay conditions.
HPLC analysis ofcellular nucleotide pools and
thiopurine incorporation into nucleic acids
Intracellular concentrations of endogenous purine
and pyrimidine ribonucleoside triphosphates were
determined by HPLC separation of perchloric acid
extracts on a strong anion exchange column as
described previously (Tidd & Dedhar, 1978). Nucleic
acid hydrolyzates were analyzed for 6-thioguanine
nucleotides by HPLC with fluorescence detection
following alkaline permanganate oxidation (Tidd &
Dedhar, 1978).
Results
The growth of thiopurine-resistant L1210/MPR cell
cultures was unaffected by MPR at a concentration
of I mM, and by MPRP at 2mM (data not shown).
In contrast, proliferation of these cells was inhibited
by high concentrations of bis(MPR)P (Figure 1).
These results suggest that the effects of bis(MPR)P
on Ll210/MPR cells resulted from cellular uptake
of the intact molecule since MPRP and MPR were
its extracellular degradation prcducts, formed for
the most part by the action of enzymes in the
serum component of the culture medium (Tidd et
al., 1982b). The considerable scatter of the data of
Figure 1 reflects the varying levels of activity of
phosphodiesterase I present in different batches of
horse serum and consequently the variable rates of
extracellular destruction of bis(MPR)P in these
experiments. The filled circles represent the effects
of bis(MPR)P on L1210/MPR cells growing in
medium containing 2% Ultroser G serum substitute
and demonstrate the maximum possible effects of
the drug derivative on these cells when no
exogenous phosphodiesterase activity is present. As
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Figure 1 Culture growth dose-response curves for 3
day exposure of L1210/MPR cells to bis(MRP)P and
bis(dibut.MPR)P. Data from 20 separate experiments
with several different batches of the drugs are plotted,
and each point is the mean of 2-3 replicates: (0)
bis(MPR)P; (@) bis(MPR)P, cells grown in medium
containing 2% Ultroser G serum substitute as
replacement for horse serum; (A) bis(dibut.MPR)P.
would be expected the differences from serum-
containing medium were greatest at lower
concentrations of bis(MPR)P. Bis(dibut.MPR)P
was consistently more effective than bis(MPR)P
against the HGPRT-deficient L1210/MPR cells
even when grown with serum substitute. This would
support our earlier conclusion that the enhanced
activity of bis(dibut.MPR)P over bis(MPR)P results
both from an increased resistance to degradation by
serum enzymes and a more rapid cellular uptake of
the lipophilic molecules. The dose response curve
for the combination of bis(MPR)P and 4
equivalents of sodium butyrate was no different
from that of bis(MPR)P alone (data not shown). In
the case of bis(dibut.MPR)P the variability in
efficacy (Figure 1) may be related to the observed
time dependent irreversible binding of the
compound to serum protein(s) (Tidd et al., 1982b).
When the detailed effects of bis(dibut.MPR)P on
L1210/MPR cell growth curves were investigated it
was found that approximately 1 cell 'doubling was
usually achieved during the first 20h of exposure to
the butyrated derivative before growth was arrested
(Figure 2a). Cell proliferation resumed following a
period of growth inhibition in cultures exposed to
low concentrations of bis(dibut.MPR)P, and at
higher concentrations there was no appreciable
drop in particle numbers recorded by the Coulter
Counter over 10 days. In addition, culture growth
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Figure 2 Effects of bis(dibut.MPR)P on the proliferation of L1210/MPR cells. Drug solutions were added to
replicate cultures at Oh. (a) (0) 31MM; (A) 62MM; (V) 125 pM; (El) 250,uM; (0) untreated control. (b) (V)
125 pM; (V) 125 pM, cells washed and resuspended in drug-free medium at the indicated times; (0) untreated
control.
was able to recommence when cell samples from a
culture inhibited by 125,uM bis(dibut.MPR)P for
up to 11Oh were washed free of the drug and
resuspended in fresh drug-free medium (Figure 2b).
Beyond Oh cell numbers fell following removal of
the drug, probably because the washing process
accelerated the subsequent disintegration of dead
cells. At first sight these observations might suggest
that the action of bis(dibut.MPR)P on L1210/MPR
cells was predominantly cytostatic rather than
cytotoxic at low concentrations.
Both bis(MPR)P and bis(dibut.MPR)P induced
profound shifts to smill particle size in the cell
volume distributions of L1210/MPR cultures (data
not shown). The effects of bis(dibut.MPR)P were
elicited more rapidly than were those of
bis(MPR)P. The median cell volume decreased to
60% of the control value during -72h exposure to
mM bis(MPR)P whereas the same response was
achieved during 32h incubation with 250 pM
bis(dibut.MPR)P. In contrast, sodium butyrate, a
breakdown product of bis(dibut.MPR)P, induced
an increase rather than a decrease in cell size at a
concentration of 1 mM.
In order to determine the integrity of
L1210/MPR cells inhibited by bis(dibut.MPR)P the
vital stain, trypan blue was added to samples of the
cultures and staining and non-staining cells were
counted in a haemocytometer. After 26 h exposure
to 90, 155 and 180,uM bis (dibut.MPR)P there were
small but significant increases in the proportion of
staining cells relative to untreated controls whereas
35% of cells exposed to a 310,pM concentration of
the derivative were stained (data not shown).
Further incubation of the cells with the drug
resulted in a rapid decline in the proportion of non-
staining cells and by the second day most of the
cells were dead at all four concentrations, although
the lysed cells remained sufficiently intact to be
registered by the Coulter cell counter used to obtain
the data of Figure 2.
Further evidence for the cytotoxic action of
bis(dibut.MPR)P on L1210/MPR cells was obtained
using a cloning assay for cell survival in which
known numbers of cells exposed to the drug for 3
days were washed and resuspended in drug-free soft
agar medium and incubated further until
macroscopic cell colonies derived from single
surviving cells could be counted. The results of two
such experiments are presented in Figure 3. Here
the closed symbols depict the dose-response curves
for culture growth over the three day drug
treatment period whilst the open symbols represent
the percentage of viable stem cells, relative to
untreated controls, present in these cultures at the
time that drug exposure was terminated. It can be
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Figure 3 Dose-response curves for 3-day treatment of L1210/MPR cell cultures with bis(dibut.MPR)P. (0)
increase in cell number over 3-day treatment period relative to that in untreated control cultures; data,
mean+s.e. (vertical bars) 2 replicates. (0) percent survival, plating efficiency of treated cells relative to that
of untreated controls; data, mean+s.e. (vertical bars) 5 replicates. Panels a and b, results of two separate
experiments.
seen that contrary to expectations for a cytostatic
drug, bis(dibut.MPR)P was significantly more
effective in killing or sterilizing cells than in
inhibiting growth over a 3-day exposure period. A
cytostatic drug would be expected to produce a
declining dose-response curve for culture growth
whilst cell viability would remain at 100%.
Dibut.MPRP may be looked upon as a butyrated
drug nucleotide control for bis(dibut.MPR)P, since
the fornmer is a plausible degradation product of the
latter and also both compounds would generate the
same extracellular breakdown products in cell
cultures, namely dibutyryl MPR, butyric acid, and
MPR. The culture growth dose-response curves of
bis(dibut.MPR)P and dibut.MPRP against
L1210/MPR cells are compared in Figure 4.
Dibut.MPRP did inhibit growth of L1210/MPR
cultures to some extent but the degree of inhibition
was considerably less than that of bis(dibut.MPR)P.
This would suggest that the effects of
bis(dibut.MPR)P on L1210/MPR cells probably
resulted from cellular uptake of the derivative as
such, at least as the initial step in its action of these
cells. In contrast, the predominant mechanism of
action of bis(dibut.MPR)P on wild type,
thiopurine-sensitive L1210/0 cells is almost certainly
mediated through release of MPR and hence the
derivative is less effective than the parent drug
against these HGPRT-positive cells (Tidd et al.,
1982b). This would appear to be true also of
dibut.MPRP since the culture growth dose-response
curves for the two butyrated derivatives against
L1210/0 cells were identical (data not shown). The
culture growth dose-response curve for
bis(dibut.MPR)P against L1210/0 cells was
displaced to higher drug concentration by a factor
of - 6 along the abscissa from the cell viability
(cloning assay) dose-response curve (data not
shown). This observation is typical of the delayed
cytotoxic action of the thiopurines where sterilized
cells may divide once or twice before they lyse
(Tidd & Paterson 1974a, b).
We have previously reported that bis(MPR)P was
no different from MPR in terms of its effect on
HGPRT-deficient V79 Chinese hamster lung
fibroblasts, CH/TG (Tidd et al., 1982b). The
culture growth dose-response curves for MPR and
bis(dibut.MPR)P against this cell line are presented
in Figure 5. It can be seen that in contrast to the
results with bis(MPR)P, bis(dibut.MPR)P was
considerably more effective than MPR. The EC65
value (concentration giving 65% of control growth)
for MPR was 7.5 x 10-4M whilst the EC65 value
for bis(dibutyryl MPR)P was 300 x lower at
2.5 x 10-6M. The effects of bis(dibut.MPR)P on
growth of CH/TG cells over a 3-day exposure
period were compared with the ability of cells
treated for 3 days to produce macroscoprc colonies6-MERCAPTOPURINE NUCLEOTIDE DERIVATIVES 511
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Figure 4 Culture growth dose-response curves for 3-
day exposure of L1210/MPR cells to MPR,
dibut.MPRP and bis(dibut.MPR)P. Data, mean+s.e.
(vertical bars) 3 replicates. (0) MPR; (0)
dibut.MPRP; (A) bis(dibut.MPR)P.
Figure 5 Culture growth dose-response curves for 3-
day exposure of thiopurine-resistant CH/TG cells to
MPR and bis(dibut.MPR)P. Data, mean of 4
replicates; vertical bars. 95% confidence limits. (0)
MPR; (0) bis(dibut.MPR)P.
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Figure 6 Incorporation of [3H]thymidine into acid soluble nucleotides and DNA of CH/TG cells. (a)
untreated control cells. (b) cells exposed to 100pM bis(dibut.MPR)P for 4h. (0) radioactivity in acid soluble
nucleotides; (Q) radioactivity in DNA.
following removal of the drug. These experiments
demonstrated that as in the case of L1210/MPR
cells, bis(dibut.MPR)P was also cytotoxic to the
thiopurine-resistant Chinese hamster cells (data not
shown).
Bis(dibut.MPR)P (1OOPM, 4h) inhibited
incorporation of [3H] thymidine into DNA of
CH/TG cells (Figure 6b). Following drug exposure,
phosphorylation of [3H]-thymidine to acid soluble
nucleotides (Figure 6b) was inhibited by -36%
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relative to. untreated controls (Figure 6a) but this
could not account for the total suppression of
incorporation into DNA.
Further studies on incorporation of radiolabelled
precursors by L1210/MPR cells demonstrated that
continuous exposure to 1 mM bis(MPR)P induced a
progressive decline in the ability of cell samples to
incorporate [3H]-uridine into RNA during 10min
incubation periods (Figure 7a). This was followed
by a fall in the capacity of cells to incorporate [3H]-
thymidine into DNA and finally in a reduction in
the rate of uptake of [3H]-leucine into acid
precipitable material (Figure 7a). In the case of
bis(dibut.MPR)P the effects on precursor incor-
poration by L1210/MPR cells were similar to those
of bis(MPR)P except that they were elicited much
more rapidly by a lower concentration (250 pM) of
the derivative (Figure 7b). The mechanisms of
inhibition of isotope incorporation remain to be
determined. These results do not necessarily imply
that cellular macromolecular synthesis was inhibited
since defects in precursor transport or phos-
a
phorylation could equally well account for the data.
Cytotoxic concentrations of bis(MPR)P and
bis(dibut.MPR)P had no effect on the intracellular
concentrations ofendogenous purine and pyrimidine
ribonucleoside triphosphates in L1210/MPR cells,
as determined by HPLC analysis of perchloric acid
extracts (data not shown). In addition, all attempts
failed to detect any 6-thioguanine nucleotides
incorporated in the DNA and RNA of L1210/MPR
cells exposed to lethal concentrations of the two
drug derivatives. In contrast, 6-thioguanine
nucleotides were readily measured in hydrolysates
of the nucleic acids from L1210/0 cells treated with
bis(MPR)P and bis(dibut.MPR)P.
Discussion
The data presented in this paper demonstrate that
bis(dibut.MPR)P had a predominantly cytotoxic
action against HGPRT-deficient cells. The recovery
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Figure 7 Effects of continuous exposure to bis(MPR)P and bis(dibut.MPR)P on the ability of L1210/MPR
cells to incorporate [3H] thymidine, [3H] uridine and [3H] leucine separately into macromolecules. (a) 1 mM
bis(MPR)P. (b) 250uM bis(dibut.MPR)P. Data, mean of at least 5 measurements; vertical bars, 95%
confidence limits; expressed as percentages of the incorporations by untreated control cells. (A) [3H] uridine;
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of cell proliferation in cultures exposed to low
concentrations of bis(dibut.MPR)P (Figure 2a)
represented the outgrowth of surviving cells which
occurred as the available concentration of the
derivative decreased. We have previously reported
that the concentration of free bis(dibut.MPR)P
declined during incubation at 37°C in tissue culture
medium, due, apparently, to irreversible binding of
the derivative to serum protein(s) (Tidd et al.,
1982b). Cells killed by bis(dibut.MPR)P did not
disintegrate to particles smaller than the lower
threshold limit of the Coulter Counter, and
consequently they continued to be registered by the
counter over extended periods (Figure 2). However,
the cells were dead by the criterion of trypan blue
exclusion and ability to produce macroscopic
colonies in soft agar medium. Again, the recovery
of cell growth following removal of the drug
containing medium (Figure 2b) represented the
outgrowth of cells surviving treatment at each time
point, rather than release of the entire cell
population from reversible inhibition of cell
division.
Both bis(MPR)P and bis(dibut.MPR)P induced
successive inhibitions of incorporation of
radiolabelled precursors into RNA, DNA and
finally protein in L1210/MPR cells (Figure 7).
These effects were produced more rapidly and at
lower concentration by bis(dibut.MPR)P than by
bis(MPR)P suggesting that cellular uptake of
bis(dibut.MPR)P was indeed enhanced over that of
bis(MPR)P by the lipophilic butyryl groups.
Similarly the decrease in cell size in L1210/MPR
cultures was induced more rapidly by
bis(dibut.MPR)P than by bis(MPR)P.
The much lower efficacy of dibut.MPRP than
bis(dibut.MPR)P in inhibiting growth of
L1210/MPR cultures (Figure 4) provides further
support for the conclusion that the action of the
latter derives from the initial uptake of the intact
molecule by cells rather than from its extracellular
breakdown products. Phosphodiesterase cleavage of
bis(dibut.MPR)P, if it occurred, would produce
dibut.MPRP and dibutyryl MPR, whilst phospho-
hydrolases would also release dibutyryl MPR from
dibut.MPRP. It is also apparent that release of
butyric acid did not contribute significantly to the
action of bis(dibut.MPR)P against L1210/MPR
cells since bis(dibut.MPR)P and dibut.MPRP would
be expected to be roughly equivalent in this
process, and in addition, sodium butyrate was
shown to induce an increase rather than a decrease
in cell size. Conversely, the activities of
dibut.MPRP and bis(dibut.MPR)P against
thiopurine-sensitive L1210/0 cells were similar and
were lower than that of MPR which is consistent
with a predominant mechanism of action against
HGPRT-positive cells involving drug breakdown
with release of MPR. Presumably these cells
convert MPR to MP by phosphorolysis and thence
to MPRP by HGPRT.
Data demonstrating the cytotoxic effects of
bis(dibut.MPR)P against HGPRT-deficient CH/TG
cells are presented in view of the earlier observation
that the non-butyrated derivative, bis(MPR)P was
no more effective than MPR against the thiopurine-
resistant cell line (Tidd et al., 1982b). This result is
significant since it indicates that the activity of
bis(dibut.MPR)P is not peculiar to the L1210/MPR
subline, but is also observed in cells which attach to
surfaces. Bis(dibut.MPR)P was shown to inhibit
incorporation of [3H]-thymidine into DNA of
CH/TG cells (Figure 6), and although drug
treatment did reduce somewhat the incorporation
of radiolabelled precursor into acid-soluble
nucleotide pools, this effect was insufficient to
account for the arrest of DNA incorporation,
suggesting that the derivative might have a more
direct action on the process of DNA replication.
Since bis(MPR)P and bis(dibut.MPR)P had no
effect on the intracellular concentrations of
physiological nucleotides in L1210/MPR cells and
neither were incorporated into nucleic acids of the
HGPRT-deficient cells as 6-thioguanine nucleotide
metabolites, it may be concluded that intracellular
bis(MPR)P derived from extracellular bis(MPR)P
or bis(dibut.MRP)P was acting as such to induce
the observed effects rather than as a prodrug of
MPRP. It may well be that the idea of an
antimetabolite nucleoside monophosphate prodrug
is ill founded, since in most cases it is likely that
the combined rate of uptake of the prodrug and
intracellular release of the monophosphate will not
exceed the rate of dephosphorylation of the latter
by cellular phosphohydrolases/nucleotidases, and in
the absence of nucleotide regenerating enzymes,
such as HGPRT, a significant intracellular
concentration of drug nucleoside monophosphate
may not be achieved. The maintenance of mono-
phosphate concentrations in drug sensitive cells is
probably a dynamic process involving abortive
cycles of dephosphorylation and rephosphorylation,
hence the extensive excretion of hypoxanthine by
HGPRT -ve cells (Tidd, 1984). There has only been
scant evidence for true circumvention of resistance
by nucleoside monophosphate prodrugs, and then
mainly at excessive concentrations of the
compounds (For review see Tidd, 1984). Indeed,
Farquhar et al. (1983) have reported that logically
designed neutral prodrug derivatives of 5-fluoro-
2'deoxyuridine 5'-phosphate were ineffective against
a 5-fluorouracil resistant mutant of leukaemia P-
388. It would appear that the main activity of the
prodrugs has resulted from their ability to behave
as slow release depot derivatives of the parent
drugs, to which the cells responding were also514 H.P. JOHNSTON et al.
sensitive. Efforts to circumvent resistance with
nucleotide prodrugs might possibly be more
successful if higher levels of phosphorylation were
employed. In this way the released antimetabolite
nucleotides would not be immediately susceptible to
rapid dephosphorylation by phosphohydrolases.
However, the design of such prodrugs faces the
problem that additional negative charges on the
molecules would have to be reversibly masked.
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